Anthem Biosciences Limited successfully concluded its 20th Annual General Meeting on July 22, 2026, approving the audited financial statements for the financial year ended March 31, 2026. The meeting, held via Video Conferencing and Other Audio-Visual Means, saw the adoption of the Board of Directors' report and the Auditors' report. The statutory auditors' reports for FY 2025-26 contained no qualifications, reservations, or adverse remarks.

Key Resolutions Passed

The shareholders transacted several businesses through remote e-voting prior to and following the meeting. All resolutions were passed with the requisite majority. The key ordinary and special businesses included the approval of financial statements, dividend declaration, and the appointment of auditors.

Ordinary Business

The meeting approved the adoption of the audited financial statements, including consolidated financial statements, for the year ended March 31, 2026. Shareholders also approved the declaration of dividend and the re-appointment of Mr. K Ravindra Chandrappa (DIN: 01580534), who retires by rotation and was eligible for re-appointment.

Auditor and Director Appointments

In a significant decision, the members appointed M/S. S.R. Batliboi & Associates LLP (FRN 101049W/ E300004) as the statutory auditors of the company. Additionally, the meeting approved the continuation of Mr. Ravikant Uppal (DIN: 00025970) as a non-executive independent director upon attaining the age of 75 years, which was passed as a special resolution.

Remuneration and Related Party Approvals

The AGM also sanctioned the commission payable to Independent Directors and approved an increase in the payment of remuneration to related parties holding an office or place of profit. Furthermore, the shareholders approved the Upside Sharing Arrangement with Viridity Tone LLP.

Mr. Ajay Bhardwaj, Chairperson, Managing Director, and Chief Executive Officer, chaired the meeting. The proceedings were overseen by Ms. Divya Prasad, Company Secretary and Compliance Officer. Mr. Pramod S M of M/s. BMP & Co. LLP acted as the Scrutinizer for the e-voting process.

Anthem Biosciences reported a 22.6% year-on-year decline in consolidated revenue from operations to ₹4,182 Mn for the quarter ended June 30, 2026. The company attributed the decline to timing shifts in deliveries to key customers, noting that underlying demand remains strong with a higher concentration of scheduled deliveries expected in the latter half of the year. Consolidated profit after tax (PAT) decreased by 11.7% to ₹1,199 Mn, while EBITDA margins expanded by 153 basis points to 39.6% despite the revenue drop.

Consolidated Financial Performance

The CRDMO segment led revenue generation with ₹3,408 Mn, while the Specialty Ingredients segment contributed ₹774 Mn. On a year-on-year basis, CRDMO revenue fell 24.7% and Specialty Ingredients revenue declined 11.5%. Total consolidated expenses for the quarter stood at ₹2,985.25 Mn. The company reported a net cash position of ₹17,197 Mn as of June 30, 2026, compared to ₹7,848 Mn in the prior year.

Standalone Financial Performance

Standalone revenue from operations fell to ₹3.84B compared to ₹5.38B in the same period last year. Standalone net profit declined to ₹1.02B versus ₹1.48B in the prior year period. The standalone EBITDA for the quarter came in at ₹1.31B, with an EBITDA margin of 34.08%, contracting from 36.32% in the same quarter last year. The Statutory Auditors, K. P. Rao & Co., issued a Limited Review Report expressing an unmodified opinion on the results.

Corporate Actions and Outlook

During the quarter, the company allotted 1,670,909 fully paid-up equity shares of ₹2 each under the ESOP Scheme 2024. The paid-up equity share capital post-allotment increased to ₹1,126.77 Mn. Management emphasized that disciplined focus on cost efficiencies, yield optimisation, and employee productivity reinforced the industry-leading margin profile, positioning the company to sustain performance through the year.

Regulatory Disclosure

Pursuant to Regulation 30 and Regulation 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, the company informed the exchanges that the audio recording of the Earnings Call for the quarter ended June 30, 2026, held on Wednesday, July 22, 2026, has been made available on its website.